ITPC MENA has extensive experience working on intellectual property (IP) and access to medicines in Morocco and across the MENA region. The organization has been at the forefront of advocacy and policy change, aiming to improve access to essential medicines.
In 2016, ITPC MENA pioneered a post-voluntary licence (VL) strategy for dolutegravir (DTG), leading to Morocco’s inclusion in the DTG license. The organization coordinates the MENA Community Advisory Board (MENACAB) and provides frequent IP training for stakeholders across MENA and francophone Africa. ITPC MENA conducted the first-ever opposition to a patented medicine in Morocco and has engaged with local pharmaceutical manufacturers to increase access to medicines. Due to its strong track record, expertise, and established relationships with key stakeholders, including institutions, ministries, civil society organizations (CSOs), and manufacturers, ITPC MENA is a key driver of progress on IP and medicine access across the region.